Medifast - MED Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

2 brokers have issued 1 year price objectives for Medifast's stock. Their MED share price forecasts range from $106.00 to $150.00. On average, they expect the company's share price to reach $128.00 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $115.35 at the start of the year. Since then, MED stock has decreased by 3.8% and is now trading at $111.00.
View the best growth stocks for 2023 here.

Medifast saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 589,500 shares, an increase of 17.8% from the December 31st total of 500,400 shares. Based on an average trading volume of 138,400 shares, the short-interest ratio is presently 4.3 days. Approximately 5.5% of the shares of the stock are short sold.
View Medifast's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) issued its quarterly earnings results on Thursday, November, 3rd. The specialty retailer reported $3.32 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $1.41. The specialty retailer earned $390.40 million during the quarter. Medifast had a trailing twelve-month return on equity of 89.82% and a net margin of 9.22%.

Medifast declared a quarterly dividend on Thursday, December 8th. Shareholders of record on Tuesday, December 20th will be given a dividend of $1.64 per share on Tuesday, February 7th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 5.91%. The ex-dividend date of this dividend is Monday, December 19th.
Read our dividend analysis for MED.

Medifast (NYSE:MED) pays an annual dividend of $6.56 per share and currently has a dividend yield of 5.74%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 49.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 49.47% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MED.

Medifast updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $11.61-$13.05 for the period, compared to the consensus earnings per share estimate of $12.28. The company issued revenue guidance of $1.51 billion-$1.59 billion, compared to the consensus revenue estimate of $1.60 billion.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (2.46%), Chickasaw Capital Management LLC (0.26%), Allspring Global Investments Holdings LLC (0.20%), New York State Teachers Retirement System (0.17%), Campbell Newman Asset Management Inc. (0.14%) and National Bank of Canada FI (0.08%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $111.00.

Medifast (NYSE:MED) has a market capitalization of $1.21 billion and generates $1.53 billion in revenue each year. The specialty retailer earns $164.03 million in net income (profit) each year or $13.19 on an earnings per share basis.

The company employs 984 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.